Sentences with phrase «treats lung cancer patients»

Cancer Research UK scientists in Oxford are trialling an experimental drug to treat lung cancer patients who have stopped responding to initial chemotherapy treatment.

Not exact matches

They'll also jointly market Pfizer's drug Xalkori, which is approved in more than 75 countries for treating non-small cell lung cancer in patients with a certain genetic mutation.

The proportion of patients treated within 62 days of an urgent GP referral for various cancer types is as follows: Lung cancers — 83.3 % treated within 62 days of an urgent GP referral for suspected cancer.

Gemcitabine is used to treat patients with pancreatic, lung, breast and bladder cancers.

Urbanic said the overall findings of the study suggest that there are some patients with recurrent lung cancers who can be treated with another definitive course of radiation therapy and still have a chance at a cure.

The median age was 66 and the majority of patients (88 percent) were treated for primary lung cancer.

«One of the toughest challenges of lung cancer is what to do for patients when the cancer comes back in an area that's been treated previously with radiation treatment,» said James J. Urbanic, M.D., lead author of the studies and a radiation oncologist at Wake Forest Baptist.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

«In the 20 years that I've been in practice, I consider this a major milestone,» she adds, noting that the trial results helped achieve U.S. Food and Drug Administration approval in March to treat such patients whose lung cancer progressed, despite standard chemotherapy.

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fightPatients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fightpatients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

The team studied a lung cancer drug called erlotinib which can be used to treat between 10 and 30 per cent of lung cancer patients.

In addition, the study showed that the 5 - year survival rate for selected older patients with advanced lung cancer who were treated with surgical therapy was 29.9 % for Stage III and 26.7 % for Stage IV.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

This shows promise for breast cancer patients as diagnosing and treating the breast cancer at early stages means there is a greater chance of preventing cancer cells spreading to other tissues, such as the lungs, brain and bone.

The study, called «Molecular Determinants of Drug - Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patieLung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patCancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patielung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patcancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients.

When William Pao was a medical oncology fellow at Memorial Sloan Kettering Cancer Center (MSKCC) during the early 2000s, treating patients with metastatic non-small cell lung cancer (NSCLC) was rote: Every patient received the same chemotherapy reCancer Center (MSKCC) during the early 2000s, treating patients with metastatic non-small cell lung cancer (NSCLC) was rote: Every patient received the same chemotherapy recancer (NSCLC) was rote: Every patient received the same chemotherapy regimen.

In a letter published in the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapy.

Prof Soria will say: «Eventually, almost all lung cancer patients with EGFR mutations will develop resistance to currently available therapies, including TKI, leaving doctors and patients without effective options to treat this deadly disease.

«Lung cancer patients are usually treated with chemo, and they can do well, but you seldom see dramatic turnarounds,» Shaw says.

«In this study, outcomes for HER2 - positive lung cancer patients treated with conventional therapies were similar to outcomes for HER2 - negative patients treated in the same way.

With the advancement of surgical and radiation therapy strategies for stage 1 non-small-cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online today in The Annals of Thoracic Surgery.

The booklet has been developed and reviewed by medical experts who treat patients with lung cancer.

The purpose of this study is to compare the effectiveness of daratumumab in combination with atezolizumab against atezolizumab alone in patients who have advanced non-small cell lung cancer (NSCLC) that has previously been treated.

«The authors report the effect on the «HIV reservoir» of injections of a monoclonal anti-PD1 antibody, nivolumab, given to a patient with long standing HIV to treat relapsed lung cancer.

Novel strategies that are effective in treating brain metastases in patients with lung cancer are needed.

Long - term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole - brain radiotherapy and thoracic chemoradiation.

DENVER — Elderly patients with stage III non-small cell lung cancer (NSCLC) showed improved overall survival (OS) when treated with chemoradiation (CRT) compared to definitive radiation (RT) alone.

Combining physical and biologic parameters to predict radiation - induced lung toxicity in patients with non-small-cell lung cancer treated with definitive radiation therapy.

Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.

10/7/2008 Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaccLung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaCancer Vaccine Trial Launched at Moores UCSD Cancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaCancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaCancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vacclung cancer by treating patients with a novel kind of cancer vacancer by treating patients with a novel kind of cancer vacancer vaccine.

Prognosis of lung cancer is poor; around 7 % of patients survive for five years, and most patients are treated palliatively from diagnosis.

One reason is that the majority - 65 - 75 per cent - of lung cancer patients are diagnosed when the cancer has already become aggressive, which makes it more difficult to treat successfully.

The discovery could change the approach to treating even the smallest lung cancers — the size of a pea — which are known to recur within five years in 30 to 40 percent of patients.

Together, this work will further our understanding of lung cancer biology and create insight toward the development of new approaches to diagnose and treat patients suffering from this disease.

Taxotere is a chemotherapy drug that treats patients by killing cancer cells, especially those of the breast, lungs, stomach, prostate, neck, and head.